Published in Nat Biotechnol on March 28, 2016
Early Detection of Four Common Cancers Using the ctDNA Analysing Test (K-DETEK) | NCT05227261
Phylogenetic ctDNA analysis depicts early stage lung cancer evolution. Nature (2017) 2.54
Circulating tumour DNA profiling reveals heterogeneity of EGFR inhibitor resistance mechanisms in lung cancer patients. Nat Commun (2016) 1.13
Circulating tumor DNA analysis detects minimal residual disease and predicts recurrence in patients with stage II colon cancer. Sci Transl Med (2016) 1.06
Integrating liquid biopsies into the management of cancer. Nat Rev Clin Oncol (2017) 0.94
Liquid biopsies come of age: towards implementation of circulating tumour DNA. Nat Rev Cancer (2017) 0.88
Detecting very low allele fraction variants using targeted DNA sequencing and a novel molecular barcode-aware variant caller. BMC Genomics (2017) 0.87
Fragment Length of Circulating Tumor DNA. PLoS Genet (2016) 0.87
Liquid biopsy based biomarkers in non-small cell lung cancer for diagnosis and treatment monitoring. Transl Lung Cancer Res (2016) 0.80
Liquid Biopsies for Cancer: Coming to a Patient near You. J Clin Med (2017) 0.78
Circulating biomarkers to monitor cancer progression and treatment. Comput Struct Biotechnol J (2016) 0.78
Current and Emerging Applications of Droplet Digital PCR in Oncology. Mol Diagn Ther (2017) 0.76
Role of KEAP1/NRF2 and TP53 Mutations in Lung Squamous Cell Carcinoma Development and Radiation Resistance. Cancer Discov (2016) 0.76
Circulating tumor cells versus circulating tumor DNA in lung cancer-which one will win? Transl Lung Cancer Res (2016) 0.76
Circulating Tumor Cells (CTC) and Cell-Free DNA (cfDNA) Workshop 2016: Scientific Opportunities and Logistics for Cancer Clinical Trial Incorporation. Int J Mol Sci (2016) 0.76
Circulating tumor DNA as a liquid biopsy target for detection of pancreatic cancer. World J Gastroenterol (2016) 0.75
Blood-Based Analysis of Circulating Cell-Free DNA and Tumor Cells for Early Cancer Detection. PLoS Med (2016) 0.75
TP53 mutations on circulating cell-free DNA. EBioMedicine (2016) 0.75
Individualised multiplexed circulating tumour DNA assays for monitoring of tumour presence in patients after colorectal cancer surgery. Sci Rep (2017) 0.75
The Pursuit of Noninvasive Diagnosis of Lung Cancer. Semin Respir Crit Care Med (2016) 0.75
Technological considerations for genome-guided diagnosis and management of cancer. Genome Med (2016) 0.75
Novel computational method for predicting polytherapy switching strategies to overcome tumor heterogeneity and evolution. Sci Rep (2017) 0.75
Asymmetrical barcode adapter-assisted recovery of duplicate reads and error correction strategy to detect rare mutations in circulating tumor DNA. Sci Rep (2017) 0.75
Liquid biopsy genotyping in lung cancer: ready for clinical utility? Oncotarget (2017) 0.75
Capturing Genomic Evolution of Lung Cancers through Liquid Biopsy for Circulating Tumor DNA. J Oncol (2017) 0.75
Emerging concepts in liquid biopsies. BMC Med (2017) 0.75
Liquid Biopsy in Non-Small Cell Lung Cancer. Front Med (Lausanne) (2016) 0.75
ERBB2-Mutated Metastatic Non-Small Cell Lung Cancer: Response and Resistance to Targeted Therapies. J Thorac Oncol (2017) 0.75
Risk for molecular contamination of tissue samples evaluated for targeted anti-cancer therapy. PLoS One (2017) 0.75
Statistical analysis of mutant allele frequency level of circulating cell-free DNA and blood cells in healthy individuals. Sci Rep (2017) 0.75
Clinical validation of a highly sensitive assay to detect EGFR mutations in plasma cell-free DNA from patients with advanced lung adenocarcinoma. PLoS One (2017) 0.75
Circulating Tumor DNA for Mutation Detection and Identification of Mechanisms of Resistance in Non-Small Cell Lung Cancer. Mol Diagn Ther (2017) 0.75
Management of EGFR-mutated non-small-cell lung cancer: practical implications from a clinical and pathology perspective. Curr Oncol (2017) 0.75
Cell-free DNA copy number variations in plasma from colorectal cancer patients. Mol Oncol (2017) 0.75
Circulating Tumor DNA as Biomarkers for Cancer Detection. Genomics Proteomics Bioinformatics (2017) 0.75
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med (2011) 16.94
Analysis of circulating tumor DNA to monitor metastatic breast cancer. N Engl J Med (2013) 13.22
COSMIC: exploring the world's knowledge of somatic mutations in human cancer. Nucleic Acids Res (2014) 10.77
Circulating mutant DNA to assess tumor dynamics. Nat Med (2007) 10.33
High-throughput droplet digital PCR system for absolute quantitation of DNA copy number. Anal Chem (2011) 10.11
Emergence of KRAS mutations and acquired resistance to anti-EGFR therapy in colorectal cancer. Nature (2012) 8.77
Detection of circulating tumor DNA in early- and late-stage human malignancies. Sci Transl Med (2014) 8.36
Non-invasive analysis of acquired resistance to cancer therapy by sequencing of plasma DNA. Nature (2013) 7.42
Detection and quantification of rare mutations with massively parallel sequencing. Proc Natl Acad Sci U S A (2011) 6.29
Rociletinib in EGFR-mutated non-small-cell lung cancer. N Engl J Med (2015) 6.28
Detection of ultra-rare mutations by next-generation sequencing. Proc Natl Acad Sci U S A (2012) 5.53
ACMG clinical laboratory standards for next-generation sequencing. Genet Med (2013) 5.30
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med (2014) 4.98
Liquid biopsies: genotyping circulating tumor DNA. J Clin Oncol (2014) 4.76
Accurate sampling and deep sequencing of the HIV-1 protease gene using a Primer ID. Proc Natl Acad Sci U S A (2011) 4.68
Free DNA in the serum of cancer patients and the effect of therapy. Cancer Res (1977) 4.59
Mutation tracking in circulating tumor DNA predicts relapse in early breast cancer. Sci Transl Med (2015) 3.33
Noninvasive detection of response and resistance in EGFR-mutant lung cancer using quantitative next-generation genotyping of cell-free plasma DNA. Clin Cancer Res (2014) 3.28
Acquired EGFR C797S mutation mediates resistance to AZD9291 in non-small cell lung cancer harboring EGFR T790M. Nat Med (2015) 2.88
A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer. J Mol Diagn (2010) 2.86
Circulating tumour DNA and CT monitoring in patients with untreated diffuse large B-cell lymphoma: a correlative biomarker study. Lancet Oncol (2015) 2.64
High-throughput DNA sequencing errors are reduced by orders of magnitude using circle sequencing. Proc Natl Acad Sci U S A (2013) 2.44
Gefitinib treatment in EGFR mutated caucasian NSCLC: circulating-free tumor DNA as a surrogate for determination of EGFR status. J Thorac Oncol (2014) 2.23
Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res (2011) 2.23
Broad, Hybrid Capture-Based Next-Generation Sequencing Identifies Actionable Genomic Alterations in Lung Adenocarcinomas Otherwise Negative for Such Alterations by Other Genomic Testing Approaches. Clin Cancer Res (2015) 2.12
Detection of tumor PIK3CA status in metastatic breast cancer using peripheral blood. Clin Cancer Res (2012) 2.07
Oncogenic PIK3CA mutations occur in epidermal nevi and seborrheic keratoses with a characteristic mutation pattern. Proc Natl Acad Sci U S A (2007) 1.97
Circulating tumor DNA as a liquid biopsy for cancer. Clin Chem (2014) 1.78
Discovery and characterization of artifactual mutations in deep coverage targeted capture sequencing data due to oxidative DNA damage during sample preparation. Nucleic Acids Res (2013) 1.70
Detection and Dynamic Changes of EGFR Mutations from Circulating Tumor DNA as a Predictor of Survival Outcomes in NSCLC Patients Treated with First-line Intercalated Erlotinib and Chemotherapy. Clin Cancer Res (2015) 1.59
Noninvasive monitoring of diffuse large B-cell lymphoma by immunoglobulin high-throughput sequencing. Blood (2015) 1.59
Detecting ultralow-frequency mutations by Duplex Sequencing. Nat Protoc (2014) 1.53
Sequencing small genomic targets with high efficiency and extreme accuracy. Nat Methods (2015) 1.16
Early Prediction of Response to Tyrosine Kinase Inhibitors by Quantification of EGFR Mutations in Plasma of NSCLC Patients. J Thorac Oncol (2015) 1.14
Exome Sequencing of Cell-Free DNA from Metastatic Cancer Patients Identifies Clinically Actionable Mutations Distinct from Primary Disease. PLoS One (2015) 1.10
Cerebrospinal fluid-derived circulating tumour DNA better represents the genomic alterations of brain tumours than plasma. Nat Commun (2015) 1.07
Cytosine deamination is a major cause of baseline noise in next-generation sequencing. Mol Diagn Ther (2014) 1.02
Biomarker testing and time to treatment decision in patients with advanced nonsmall-cell lung cancer. Ann Oncol (2015) 1.00
Evaluation of Hybridization Capture Versus Amplicon-Based Methods for Whole-Exome Sequencing. Hum Mutat (2015) 1.00
Challenges to implementation of an epidermal growth factor receptor testing strategy for non-small-cell lung cancer in a publicly funded health care system. J Thorac Oncol (2013) 1.00
Sample features associated with success rates in population-based EGFR mutation testing. J Thorac Oncol (2014) 0.93
Targeted single molecule mutation detection with massively parallel sequencing. Nucleic Acids Res (2015) 0.91
EGFR mutation testing practices within the Asia Pacific region: results of a multicenter diagnostic survey. J Thorac Oncol (2015) 0.88
Potential clinical utility of ultrasensitive circulating tumor DNA detection with CAPP-Seq. Expert Rev Mol Diagn (2015) 0.81
An ultrasensitive method for quantitating circulating tumor DNA with broad patient coverage. Nat Med (2014) 4.98
The prognostic landscape of genes and infiltrating immune cells across human cancers. Nat Med (2015) 2.48
Identification of recurrent SMO and BRAF mutations in ameloblastomas. Nat Genet (2014) 1.20
Fingerprints of Epstein-Barr virus in nasopharyngeal carcinoma. Nat Genet (2014) 0.75